Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce that NOX have joined with Principal Investigator, Professor Paul De Souza, and three Sydney hospitals in a pilot study (IONIC-1) to explore the ability of Veyonda® to boost the effectiveness of Bristol Myers Squibb’s nivolumab (Opdivo®) for the treatment of cancer.
The program known as IONIC stands for Immuno-Oncology with VeyoNda and Immune Checkpoint inhibitors.
Immune checkpoint inhibitors such as nivolumab have revolutionised the treatment of some cancers with what can be dramatic life-saving benefits. However, some patients have inherent resistance to immune checkpoint inhibitors and the IONIC-1 study will investigate whether Veyonda is able to overcome this resistance in patients with cancers such as breast, ovarian, prostate and sarcoma cancers.
For more information, download the attached PDF.
Download this document
